JP2022519789A - カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 - Google Patents

カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 Download PDF

Info

Publication number
JP2022519789A
JP2022519789A JP2021569596A JP2021569596A JP2022519789A JP 2022519789 A JP2022519789 A JP 2022519789A JP 2021569596 A JP2021569596 A JP 2021569596A JP 2021569596 A JP2021569596 A JP 2021569596A JP 2022519789 A JP2022519789 A JP 2022519789A
Authority
JP
Japan
Prior art keywords
hydroxyvitamin
patient
serum
shpt
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569596A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020161543A5 (enExample
Inventor
チャールズ ダブリュー ビショップ
Original Assignee
エアジェン ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアジェン ファーマ リミテッド filed Critical エアジェン ファーマ リミテッド
Publication of JP2022519789A publication Critical patent/JP2022519789A/ja
Publication of JPWO2020161543A5 publication Critical patent/JPWO2020161543A5/ja
Priority to JP2024204631A priority Critical patent/JP2025031720A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
JP2021569596A 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物 Pending JP2022519789A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024204631A JP2025031720A (ja) 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802148P 2019-02-06 2019-02-06
US62/802,148 2019-02-06
PCT/IB2020/000089 WO2020161543A1 (en) 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024204631A Division JP2025031720A (ja) 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Publications (2)

Publication Number Publication Date
JP2022519789A true JP2022519789A (ja) 2022-03-24
JPWO2020161543A5 JPWO2020161543A5 (enExample) 2023-02-14

Family

ID=69903711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569596A Pending JP2022519789A (ja) 2019-02-06 2020-02-06 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
JP2024204631A Pending JP2025031720A (ja) 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024204631A Pending JP2025031720A (ja) 2019-02-06 2024-11-25 カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物

Country Status (9)

Country Link
US (1) US20220226351A1 (enExample)
EP (1) EP3920938A1 (enExample)
JP (2) JP2022519789A (enExample)
KR (1) KR20210126023A (enExample)
CN (1) CN113573714A (enExample)
AU (2) AU2020218639A1 (enExample)
CA (1) CA3128153A1 (enExample)
MX (1) MX2020011741A (enExample)
WO (1) WO2020161543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517429A (ja) * 2013-03-15 2016-06-16 オプコ アイルランド グローバル ホールディングス リミテッド 安定化調整放出ビタミンｄ製剤及びその投与方法
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
SI2481400T1 (sl) * 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
FI3225243T3 (fi) 2007-04-25 2025-10-13 Opko Renal Llc Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
EP3112476B1 (en) 2008-04-02 2023-08-02 EirGen Pharma Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
AU2013203489B2 (en) * 2008-07-24 2015-02-05 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
EP3636280B1 (en) * 2010-03-29 2025-05-14 EirGen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7590184B2 (ja) * 2018-04-03 2024-11-26 オプコ アイルランド グローバル ホールディングス リミテッド 肥満外科手術患者におけるカルシフェジオールの使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517429A (ja) * 2013-03-15 2016-06-16 オプコ アイルランド グローバル ホールディングス リミテッド 安定化調整放出ビタミンｄ製剤及びその投与方法
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SPRAGUE, S.M., ET AL., AMERICAN JOURNAL OF NEPHROLOGY, vol. 40, no. 6, JPN6024001906, 2015, pages 535 - 545, ISSN: 0005583397 *
SPRAGUE, S.M., ET AL., EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, vol. 12, no. 5, JPN6024001907, 2017, pages 289 - 301, ISSN: 0005583396 *

Also Published As

Publication number Publication date
WO2020161543A1 (en) 2020-08-13
CN113573714A (zh) 2021-10-29
EP3920938A1 (en) 2021-12-15
CA3128153A1 (en) 2020-08-13
KR20210126023A (ko) 2021-10-19
MX2020011741A (es) 2021-03-02
US20220226351A1 (en) 2022-07-21
JP2025031720A (ja) 2025-03-07
AU2020218639A1 (en) 2021-08-12
AU2025259887A1 (en) 2025-11-20

Similar Documents

Publication Publication Date Title
AU2020267276B2 (en) Adjunctive therapy with 25-hydroxyvitamin d
AU2023200536B2 (en) Methods of vitamin D treatment
JP2017002086A (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
AU2025259887A1 (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
US11590148B2 (en) Use of calcifediol in bariatric surgery patients
HK40063649A (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
WO2025094144A1 (en) Controlling loss of kidney function
EA045627B1 (ru) Фармацевтическая композиция и набор для лечения или предотвращения гипокальциемии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241125